Print PDF

Jonathan R. Davies Ph.D.
+1 202 408 4227
jonathan.davies@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

+1 202 408 4000
Fax +1 202 408 4400

Bar and Court Admissions

  • District of Columbia
  • Maryland

Education

  • Ohio State University School of Law
    J.D., magna cum laude, 2008
  • Ohio State University
    Ph.D., Molecular Genetics, 2004
  • Pennsylvania State University
    M.S., Physiology, 1999
  • Grove City College
    B.S., Biology, 1997

Jonathan R. Davies Ph.D.

Associate

Jonathan Davies practices patent litigation, focusing on chemical, pharmaceutical, and biotechnology cases, including Hatch-Waxman litigation related to Abbreviated New Drug Applications (ANDA). His litigation experience includes numerous aspects of trial preparation, such as coordinating fact discovery, working with expert witnesses, conducting and defending fact and expert depositions, participating in hearings, and managing litigation teams. In addition to his litigation practice, Dr. Davies has experience with patent prosecution and advising clients in infringement and validity opinions.

Dr. Davies serves as an adjunct professor at American University, Washington College of Law, where he teaches a course on ANDA litigation and the Biologics Price Competition and Innovation Act (BPCIA).

Prior to joining Finnegan, Dr. Davies completed graduate studies in human physiology and conducted doctoral and post-doctoral research in cellular and molecular biology and genetics. His research focused on molecular mechanisms that regulate cellular growth and division, as well as the regulation of nuclear transport within cells.

Highlights

  • Member of a team representing Abbott Laboratories and AbbVie in Hatch-Waxman litigations over AbbVie’s HIV treatments Norvir® and Kaletra®.
  • Astellas US LLC v. Nycomed US Inc. (D.N.J.). Member of team that represented Astellas in a Hatch-Waxman litigation over its immunosuppressant drug Protopic®.
  • Eli Lilly and Co. v. Wockhardt Ltd. (S.D. Ind.). Member of team that represented Eli Lilly against multiple generic drug manufacturers in a Hatch-Waxman litigation over its drug Cymbalta®.
  • Represented pro bono a mother in a child custody case in D.C. Superior Court.
  • Represented a student in litigation related to the improper destruction of his home in D.C. Superior Court and U.S. District Court for the District of Columbia.
  • Former editor for the Ohio State Law Journal, 2007-2008.

Professional Recognition

  • Recognized as a Washington, D.C. "Rising Star" in Intellectual Property Litigation, Super Lawyers, 2014, 2015.
  • Order of the Coif.

Professional Activities

  • American Intellectual Property Law Association

Select Publications